In this article, we will take a look at some of the stocks in Eashwar Krishnan’s Tybourne Capital Management portfolio.
Eashwar Krishnan serves as the portfolio manager at Tybourne Capital Management, an investment management firm based in Hong Kong. Prior to Krishnan’s role at Tybourne Capital Management, he served as the Asia head of Lone Pine Capital for 11 years. He holds a Bachelor’s degree in Physics from St. Stephen’s College, Delhi, India, after which he did his Master’s from Cambridge University.
Eashwar Krishnan of Tybourne Capital Management
Our Methodology
We used Tybourne’s Q3 portfolio for this analysis.
8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio
8. Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM)
Tybourne Capital Management’s Stake Value: $5.5 million
Reneo Pharmaceuticals, Inc. (NASDAQ:RPHM) is essentially a clinical-stage pharmaceutical company. It focuses primarily on the development of therapies for patients with rare genetic mitochondrial diseases. Headquartered in San Diego, California, the company was founded in 2014.
Tybourne Capital Management owns a $5.5 million stake in the company.
7. Cloopen Group Holding Limited (NYSE:RAAS)
Tybourne Capital Management’s Stake Value: $5.4 million
Cloopen Group Holding Limited (NYSE:RAAS) presents cloud-based communications solutions. The company offers covering communications platform as a service (CpaaS), cloud-based contact centers and cloud-based unified communications and collaborations. Cloopen Group Holding Limited (NYSE:RAAS) also provides services to several industries including the internet, telecommunications, financial services, education, industrial manufacturing and energy.
Tybourne Capital Management owns a $5.4 million stake in Cloopen Group Holding Limited’s (NYSE:RAAS). On 3rd September, Citi initiated coverage of the stock with a “Buy” rating and a price target of $27.
6. Taysha Gene Therapies, Inc. (NASDAQ:TSHA)
Tybourne Capital Management’s Stake Value: $9.3 million
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) is a gene therapy company that primarily focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company has a Taysha Gene partnership with The University of Texas Southwestern Medical Center and with Yale University to further its research.
Tybourne Capital Management owns a $9.3 million stake in the company. As of the end of September 2021, Raju Prasad from William Blair maintained a “Buy” rating on Taysha Gene Therapies, Inc. (NASDAQ: TSHA).
5. Exicure, Inc. (NASDAQ:XCUR)
Tybourne Capital Management’s Stake Value: $8.7 million
Exicure, Inc. (NASDAQ:XCUR) is a clinical-stage biotechnology company involved in the development of therapeutics for neurology, immuno-oncology, inflammatory diseases and genetic disorders. It does all of this based on its proprietary spherical nucleic acid (SNA) technology.
Tybourne Capital Management has an $11 million stake in the company as of the third quarter.
4. Inhibrx, Inc. (NASDAQ:INBX)
Tybourne Capital Management’s Stake Value: $34.2 million
Inhibrx, Inc. (NASDAQ:INBX) is a clinical-stage biotechnology company that is focused on developing a broad pipeline of novel biologic therapeutic candidates in oncology and orphan diseases. The company also utilizes diverse methods of protein engineering to address the specific requirements of complex targets and disease biology.
Tybourne Capital Management owns a $34.2 million position in INBX as of the end of the third quarter.
3. TPG Pace Beneficial Finance Corp. (NYSE:TPGY)
Tybourne Capital Management’s Stake Value: $52 million
TPG Pace Beneficial Finance Corp. (NYSE:TPGY) is focused on effecting a merger, share exchange, asset acquisition, share purchase, reorganization.
Over the past 12 months, TPG Pace Beneficial Finance Corp. (NYSE:TPGY) is down 58%.
2. StoneCo Ltd. (NASDAQ:STNE)
Tybourne Capital Management’s Stake Value: $200 million
StoneCo Ltd. (NASDAQ: STNE) provides financial technology solutions to merchants and integrated partners. This facilitates its customers to conduct electronic commerce across in-store, online, and mobile channels in Brazil. The company concluded 2020 serving approximately 652,600 clients, most of which were small and medium-sized businesses.
Tybourne Capital Management has a huge stake in the company valued at $200 million.
In the second quarter of 2021’s investor letter, JDP Capital Management mentioned StoneCo Ltd. (NASDAQ: STNE). Here is what the letter said:
“StoneCo (NYSE: STNE) has been in our portfolio since early 2019 and has appreciated 225% since. In the first half of 2021 the stock was down nearly 20% and was a drag on the fund’s performance.
Stone is a leading fintec company in Brazil that provides back-office software, loans and other financial services to small and medium sized businesses (SMBs). We have discussed Stone in past letters and the company’s “ladder up” from a card processor to a supplier of enterprise software used to sell financial products on top of such as working capital loans…” (Click here to see the full text)
1. KE Holdings Inc. (NYSE:BEKE)
Tybourne Capital Management’s Stake Value: $299 million
KE Holdings Inc. (NYSE:BEKE) is involved in the operation of an integrated online and offline platform for housing transactions and services in the People’s Republic of China. The company operates through three segments: Existing Home Transaction Services, New Home Transaction Services and Emerging and Other Services.
KE Holdings Inc. (NYSE:BEKE) is Tybourne Capital Management’s notable holding valued at $299 million as of the third quarter.
You can also take a peek at the 10 Best Healthcare Stocks Under $20 According to Michael Castor’s Sio Capital and 10 Best Stocks Under $15 According to Billionaire Michael Price.
Follow Insider Monkey on Twitter
Suggested articles:
- Hedge Funds Aren’t Crazy About Pinduoduo Inc. (PDD) Anymore
- Otis Worldwide Corporation (OTIS) Fell Out Of Favor With Hedge Funds
- Hedge Funds Are Snapping Up Newmont Corporation (NEM)
Disclosure: None. 8 Stocks in Eashwar Krishnan’s Tybourne Capital Management Portfolio. is originally published on Insider Monkey.
